Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 3/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720341 | 1.00 | CYP2D6 (0.49) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL720740 | 1.00 | CYP2D6 (0.49) | CYP2D6LMNATHRBBLMPMP22 | |
| Cyclopentane SCHEMBL4965591 | 1.00 | CYP2D6 (0.49) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL1491629 | 0.98 | CYP2D6 (0.50) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL8199654 | 0.98 | CYP2D6 (0.50) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL1491633 | 0.98 | CYP2D6 (0.50) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL13086831 | 0.84 | CYP19A1 (0.46) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL13086832 | 0.84 | CYP19A1 (0.46) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL19105458 | 0.83 | CYP2D6 (0.51) | CYP2D6LMNATHRBBLMPMP22 | |
| SCHEMBL2541670 | 0.82 | CYP2D6 (0.47) | CYP2D6LMNATHRBBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| US-6964957-B2 | Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity | AGOURON PHARMACEUTICALS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1311511-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | Agouron Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020132319-A1 | Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | ABREO MELWYN A (US) | 2002-09-19 | — | — | US | disclosed |
| EP-1223176-A2 | Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | Agouron Pharmaceuticals, Inc. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020065292-A1 | For use in therapy of neurodegenerative diseases and certain cancers | AGOURON PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002016365-A1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132319-A1 | Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof | ERAP1, ERAP2, ERAL1 | CYP2D6 4305/4885LMNA 3488/4885THRB 1007/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | CYP2D6 2785/4885LMNA 2094/4885THRB 3793/4885 |
| US-20020065292-A1 | For use in therapy of neurodegenerative diseases and certain cancers | ERAL1, PSEN2, ERAP2 | CYP2D6 3032/4885LMNA 3205/4885THRB 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.